Yingjie Zhang

发表

Histone Deacetylase Inhibitors with Enhanced Enzymatic Inhibition Effects and Potent in vitro and in vivo Antitumor Activities

Xuejian Wang, Lei Zhang, Wenfang Xu, 2014, ChemMedChem.

Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.

Yuping Jia, Wenfang Xu, Yingjie Zhang, 2015, Journal of medicinal chemistry.

Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability.

Wenfang Xu, Yingjie Zhang, J. Hou, 2017, Bioorganic & medicinal chemistry.

Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with Indole-Containing Cap Group.

Penghui Yang, Xuejian Wang, Wenfang Xu, 2013, ACS medicinal chemistry letters.

Design and Synthesis of a Tetrahydroisoquinoline‐Based Hydroxamate Derivative (ZYJ‐34v), An Oral Active Histone Deacetylase Inhibitor with Potent Antitumor Activity

Xuejian Wang, Yuping Jia, Wenfang Xu, 2013, Chemical biology & drug design.

Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.

Xinyong Liu, Dongqing Xu, Yuan-Chao Xie, 2014, Journal of medicinal chemistry.

Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.

Wenfang Xu, Yingjie Zhang, C. Chou, 2017, Bioorganic & medicinal chemistry.

Discovery of a series of novel compounds with moderate anti-hepatitis C virus NS3 protease activity in vitro.

Wenfang Xu, Yingjie Zhang, Fangyuan Shi, 2015, Bioorganic & medicinal chemistry.

Isoform-selective histone deacetylase inhibitors: the trend and promise of disease treatment.

Wenfang Xu, Yingjie Zhang, 2015, Epigenomics.

PXD101 analogs with L‐phenylglycine‐containing branched cap as histone deacetylase inhibitors

Xiaoyan Li, Wenfang Xu, Yingjie Zhang, 2016, Chemical biology & drug design.

Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.

H. Fang, Jinhong Feng, Xuejian Wang, 2011, Journal of medicinal chemistry.

Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.

H. Fang, Jinhong Feng, Yuping Jia, 2011, European journal of medicinal chemistry.

Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.

Xiaopan Zhang, Minyong Li, B. Wang, 2010, Bioorganic & medicinal chemistry.

Inorganic Nano-Targeted Drugs Delivery System and Its Application of Platinum-Based Anticancer Drugs.

Peng Dong, Yan Zhang, Chuanzhu Gao, 2017, Journal of nanoscience and nanotechnology.

Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II.

Wenfang Xu, Yingjie Zhang, J. Zang, 2019, Bioorganic & medicinal chemistry.

Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry.

B. Wang, Wenfang Xu, Yingjie Zhang, 2018, Bioorganic & medicinal chemistry.

Design, Synthesis, and Biological Evaluation of Pyrazoline‐Based Hydroxamic Acid Derivatives as Aminopeptidase N (APN) Inhibitors

B. Wang, Wenfang Xu, Yingjie Zhang, 2018, ChemMedChem.

Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.

Jingde Wu, Xuejian Wang, Jian Zhang, 2016, Bioorganic & medicinal chemistry.

Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.

Xuejian Wang, Yuping Jia, Jian Zhang, 2016, European journal of medicinal chemistry.

Enhanced anticancer activity of 5-FU in combination with Bestatin: Evidence in human tumor-derived cell lines and an H22 tumor-bearing mouse.

Xuejian Wang, Wenfang Xu, Yingjie Zhang, 2015, Drug discoveries & therapeutics.

LJNK, an indoline-2,3-dione-based aminopeptidase N inhibitor with promising antitumor potency

Xuejian Wang, Wenfang Xu, Yingjie Zhang, 2016, Anti-cancer drugs.

Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.

Wenfang Xu, Yingjie Zhang, C. Chou, 2018, European journal of medicinal chemistry.

Novel azobenzene nickel(II) sensitizer for dye-sensitized solar cells

Xuhui Sun, Yingjie Zhang, R. Jia, 2016 .

Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.

Y. Peterson, Yingjie Zhang, C. Chou, 2018, Journal of medicinal chemistry.

Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy.

Xuejian Wang, Yuping Jia, Jian Zhang, 2018, European journal of medicinal chemistry.

Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.

Ping Wu, Yingxia Li, Wenfang Xu, 2016, European journal of medicinal chemistry.

Nitric oxide donor hybrid compounds as promising anticancer agents.

Wenfang Xu, Yingjie Zhang, Wenwen Duan, 2017, Drug discoveries & therapeutics.

Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity.

Yingjie Zhang, Chunxi Liu, Qin'ge Ding, 2020, Bioorganic chemistry.

Discovery of a fluorescent probe with HDAC6 selective inhibition.

T. Yao, Yingjie Zhang, Jin Yan, 2017, European journal of medicinal chemistry.

Progress on kinesin spindle protein inhibitors as anti-cancer agents.

Wenfang Xu, Yingjie Zhang, 2008, Anti-cancer agents in medicinal chemistry.

The structure and function of histone deacetylases: the target for anti-cancer therapy.

H. Fang, J. Jiao, Wenfang Xu, 2008, Current medicinal chemistry.

In vivo pharmacokinetic study and oral glucose tolerance test of sulfoxide analogs of GPR40 agonist TAK‐875

Wenfang Xu, Yingjie Zhang, Yugang Yan, 2020, Drug development research.

Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC

Yingjie Zhang, C. Chou, Jiangying Cao, 2020, Molecules.

Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)

Yingjie Zhang, Chunlong Zhao, Hang Dong, 2020, Expert opinion on therapeutic patents.

Design, synthesis and in vitro cytotoxicity of novel dinuclear platinum(II) complexes with a tetradentate carrier ligand: Novel dinuclear platinum(II) complexes with a tetradentate ligand

Tianshuai Wang, Bo Yang, Yingjie Zhang, 2015 .

Novel antitumor dinuclear platinum (II) complexes with a new chiral tetradentate ligand as the carrier group

Tianshuai Wang, P. Dong, Bo Yang, 2015 .

Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents

Wen Jiang, Yingjie Zhang, Y. Luan, 2021, Investigational New Drugs.

Design, Synthesis and Biological Evaluation of HDAC and VEGFR Dual Inhibitors as a Multi-targeted Anticancer Agents

Y. Liu, Yingjie Zhang, Y. Luan, 2021 .

Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.

Xinying Yang, Jian Zhang, Wenfang Xu, 2015, Bioorganic & medicinal chemistry.

Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.

Jinhong Feng, Jian Zhang, Wenfang Xu, 2014, Bioorganic & medicinal chemistry.

Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.

B. Wang, Wenfang Xu, Yingjie Zhang, 2016, Bioorganic & medicinal chemistry.

Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent

Yingjie Zhang, C. Chou, J. Zang, 2020, Frontiers in Cell and Developmental Biology.

Development of pyrazoline-based derivatives as aminopeptidase N inhibitors to overcome cancer invasion and metastasis

Yingjie Zhang, Jiangying Cao, Chunlong Zhao, 2021, RSC advances.

Design, synthesis and biological evaluation of six dinuclear platinum(II) complexes.

P. Dong, Bo Yang, Yingjie Zhang, 2017, Bioorganic & medicinal chemistry letters.

3D QSAR and docking studies of a series of histone deacetylase inhibitors

Lei Zhang, Wenfang Xu, Yingjie Zhang, 2014, Medicinal Chemistry Research.

Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity.

Jian Zhang, Wenfang Xu, Yingjie Zhang, 2015, Bioorganic & medicinal chemistry.

Discovery of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part III.

Fuming Xu, Xuejian Wang, Lei Zhang, 2014, Bioorganic & medicinal chemistry.

Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.

Hao Fang, Wenfang Xu, H. Fang, 2011, Journal of medicinal chemistry.

Synthesis and biological evaluation of N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amides as inhibitors of angiogenesis and tumor growth.

Fuming Xu, Xuejian Wang, Yuping Jia, 2013, European journal of medicinal chemistry.

Syntheses, structures and magnetic properties of tetranuclear cubane-type and heptanuclear wheel-type nickel(ii) complexes with 3-methoxysalicylic acid derivatives.

L. Lindoy, S. Hayami, Masaaki Nakamura, 2017, Dalton transactions.

Synthesis and biological evaluation of novel dinuclear platinum(II) complexes derived from a novel chiral ligand

P. Dong, Bo Yang, Yingjie Zhang, 2017 .

Applications and modifications of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) in peptides and peptidomimetics design and discovery.

H. Fang, Wenfang Xu, Yingjie Zhang, 2010, Current protein & peptide science.

Platinum(IV) antitumor complexes and their nano-drug delivery

G. Deacon, Chunyang Jia, Yingjie Zhang, 2020 .

Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors

Wenfang Xu, Yingjie Zhang, Hao Yin, 2019, Molecules.

Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors.

Hong Liu, Yingjie Zhang, Xuewu Liang, 2019, Future medicinal chemistry.

Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.

Min Huang, M. Geng, Hong Liu, 2019, Journal of medicinal chemistry.

Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors.

Wenfang Xu, Nan Zhou, Wenfang Xu, 2015, Drug discoveries & therapeutics.

Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.

Wenfang Xu, Yingjie Zhang, Xiaoyang Li, 2017, Anti-cancer agents in medicinal chemistry.

Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II.

Fuming Xu, Xuejian Wang, Yuping Jia, 2013, European journal of medicinal chemistry.

Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity

Jian Zhang, Yingjie Zhang, C. Chou, 2014, Journal of medicinal chemistry.

Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors.

B. Wang, Wenfang Xu, Yingjie Zhang, 2016 .

Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.

Yingjie Zhang, Chunlong Zhao, Wei Zhao, 2021, Bioorganic chemistry.

Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.

Jingde Wu, Wenfang Xu, Yingjie Zhang, 2017, European journal of medicinal chemistry.

Development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors: Biological evaluation and structural characterization by cocrystallization

Yingjie Zhang, Chunhua Ma, P. Sijwali, 2021, Chinese Chemical Letters.

JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases.

Wenfang Xu, Yingjie Zhang, J. Zang, 2016, Current drug targets.

Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors.

Yu Zhou, Min Huang, M. Geng, 2021, Journal of medicinal chemistry.

Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest

Huan Yang, Jian Zhang, Yingjie Zhang, 2014, Anti-cancer drugs.

Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.

Yuping Jia, Wenfang Xu, Yingjie Zhang, 2018, Journal of medicinal chemistry.

Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity.

Wenfang Xu, Yingjie Zhang, J. Zang, 2017, Bioorganic & medicinal chemistry.

Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with l-phenylglycine scaffold

Wenfang Xu, Yingjie Zhang, Xiaoguang Li, 2015, Drug Design, Development and Therapy.

Developments of polo-like kinase 1 (Plk1) inhibitors as anti-cancer agents.

Wenfang Xu, Yingjie Zhang, Shan-shan Li, 2013, Mini reviews in medicinal chemistry.

Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.

Yingjie Zhang, Hang Dong, Wei Zhao, 2021, ACS medicinal chemistry letters.

Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.

H. Fang, Jinhong Feng, Wenfang Xu, 2011, Bioorganic & medicinal chemistry.

HDAC6: physiological function and its selective inhibitors for cancer treatment.

Lei Zhang, Yingjie Zhang, Jian Zhang, 2013, Drug discoveries & therapeutics.

VEGF signal system: the application of antiangiogenesis.

Fuming Xu, Wenfang Xu, Yingjie Zhang, 2014, Current medicinal chemistry.

Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.

Jian Zhang, Wenfang Xu, Yingjie Zhang, 2017, Anti-cancer agents in medicinal chemistry.

Histone Deacetylase Inhibitors with Enhanced Enzymatic Inhibition Effects and Potent in vitro and in vivo Antitumor Activities

Xuejian Wang, Lei Zhang, Wenfang Xu, 2014, ChemMedChem.